497 1 d328367d497.htm 497 497
Prospectus Supplement dated March 15, 2022
  Prospectus Form #/Date
Product Name National New York
RiverSource ® Innovations Select Variable Annuity 45304 CH (5/21)/
May 1, 2021
45313 V (4/13) /April 29, 2013
RiverSource ® FlexChoice Select Variable Annuity 45307 CH (5/21)/
May 1, 2021
274320 J (4/13) / April 29, 2013
Evergreen New Solutions Select Variable Annuity 45308 CH (5/21)/
May 1, 2021
 
Evergreen Pathways Select Variable Annuity 45309 CH (5/21)/
May 1, 2021
 
RiverSource ® Innovations Classic Select Variable Annuity 45312 CH (5/21)/
May 1, 2021
 
RiverSource ® Builder Select Variable Annuity 45303 CH (5/21)/
May 1, 2021
 
RiverSource ® Signature Select Variable Annuity 45300 CH (5/21)/
May 1, 2021
 
RiverSource ® Signature One Select Variable Annuity 45301 CH (5/21)/
May 1, 2021
 
Wells Fargo Advantage Select Variable Annuity 45302 CH (5/21)/
May 1, 2021
 
Wells Fargo Advantage Choice Select Variable Annuity 45305 CH (5/21)/
May 1, 2021
 
The following information describes changes to certain investment options offered under certain variable annuity contracts (the “Contracts”) listed above. Please retain this supplement with your latest printed prospectus for future reference. Except as modified in this supplement, all other terms and information contained in the prospectus remain in effect and unchanged.
The investment adviser for the BNY Mellon Investment Portfolios, Technology Growth Portfolio (the Fund), BNY Mellon Investment Adviser, Inc., has engaged its affiliate, Newton Investment Management North America, LLC, to serve as the Fund's sub-adviser.


The following information will replace the current Funds’ description in the table in the “Appendix A: The Funds” or “The Variable Account and the Funds” sections of the prospectus:
Investing In Investment Objective and Policies Investment Adviser
BNY Mellon Investment Portfolios, Technology Growth Portfolio - Service Shares
Seeks capital appreciation. BNY Mellon Investment Adviser, Inc., adviser; Newton Investment Management North America, LLC, sub-adviser.
THIS SUPPLEMENT SHOULD BE READ AND RETAINED FOR FUTURE REFERENCE.
S-6720-19 A (3/22)
1